Opus Genetics Inc
NASDAQ:IRD

Watchlist Manager
Opus Genetics Inc Logo
Opus Genetics Inc
NASDAQ:IRD
Watchlist
Price: 2.27 USD 1.79% Market Closed
Market Cap: 156.5m USD

Wall Street
Price Targets

IRD Price Targets Summary
Opus Genetics Inc

Wall Street analysts forecast IRD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IRD is 7.82 USD with a low forecast of 6.06 USD and a high forecast of 9.45 USD.

Lowest
Price Target
6.06 USD
167% Upside
Average
Price Target
7.82 USD
244% Upside
Highest
Price Target
9.45 USD
316% Upside
Opus Genetics Inc Competitors:
Price Targets
185750
Chong Kun Dang Pharmaceutical Corp
35% Upside
003850
Boryung Corp
36% Upside
FAE
Faes Farma SA
15% Upside
600085
Beijing Tongrentang Co Ltd
31% Upside
JUBLPHARMA
Jubilant Pharmova Ltd
37% Upside
AXSM
Axsome Therapeutics Inc
22% Upside
JBCHEPHARM
J B Chemicals and Pharmaceuticals Ltd
12% Upside
TORNTPHARM
Torrent Pharmaceuticals Ltd
8% Upside

Revenue
Forecast

Revenue Estimate
Opus Genetics Inc

The compound annual growth rate of Opus Genetics Inc's revenue for the next 3 years is 27%.

N/A
Past Growth
27%
Estimated Growth
Estimates Accuracy
9%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Opus Genetics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

Net Income Estimate
Opus Genetics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-99%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IRD's stock price target?
Price Target
7.82 USD

According to Wall Street analysts, the average 1-year price target for IRD is 7.82 USD with a low forecast of 6.06 USD and a high forecast of 9.45 USD.

What is Opus Genetics Inc's Revenue forecast?
Projected CAGR
27%

The compound annual growth rate of Opus Genetics Inc's revenue for the next 3 years is 27%.

Back to Top